Novartis (NYSE:NVS) posted its quarterly earnings data on Tuesday. The company reported $1.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.52 by $0.14, MarketWatch Earnings reports. The firm had revenue of $12.96 billion during the quarter, compared to the consensus estimate of $12.41 billion. Novartis had a net margin of 16.31% and a return on equity of 24.15%. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.36 EPS.
Shares of Novartis stock traded up $0.74 on Thursday, reaching $91.22. 118,087 shares of the stock were exchanged, compared to its average volume of 1,509,714. The firm’s 50 day simple moving average is $90.96. Novartis has a one year low of $77.04 and a one year high of $98.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.50 and a current ratio of 0.74. The stock has a market cap of $208.78 billion, a price-to-earnings ratio of 26.24, a PEG ratio of 2.15 and a beta of 0.55.
A number of analysts have issued reports on NVS shares. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Novartis in a report on Wednesday, April 28th. Oddo Bhf raised shares of Novartis from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 28th. Deutsche Bank Aktiengesellschaft downgraded shares of Novartis from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group reissued a “buy” rating on shares of Novartis in a report on Monday, April 19th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Novartis in a report on Tuesday, May 11th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Novartis presently has a consensus rating of “Hold” and an average target price of $108.50.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.
Featured Story: Why is the ex-dividend date different from the record date?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.